Platelets as potential link between diabetes and Alzheimer's disease

Current Alzheimer Research

Volumn 11, Issue 9, 2014, Pages 862-868

  Randriamboavonjy, Voahanginirina ^a   Sopova, Kateryna ^a   Stellos, Konstantinos ^a   Laske, Christoph ^b,c  

^a GOETHE UNIVERSITY   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

Author keywords

Alzheimer s disease; Diabetes; Platelets; Vascular dementia

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADAM10 ENDOPEPTIDASE; ANTIINFLAMMATORY AGENT; APOLIPOPROTEIN E; BETA SECRETASE 1; CALPAIN; CELLUBREVIN; CILOSTAZOL; CYCLOOXYGENASE 2 INHIBITOR; CYSTEINE PROTEINASE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; HEPARIN; INSULIN RECEPTOR; INSULIN RECEPTOR SUBSTRATE 1; NONSTEROID ANTIINFLAMMATORY AGENT; RANTES; ROSIGLITAZONE; SOMATOMEDIN C RECEPTOR; SULFONYLUREA; SYNAPTOSOMAL ASSOCIATED PROTEIN 23;

ALZHEIMER DISEASE; ARTICLE; BRAIN HEMORRHAGE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COGNITIVE DEFECT; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIABETOGENESIS; DISEASE ASSOCIATION; GLUCOSE BLOOD LEVEL; HEREDITY; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; LIPID HOMEOSTASIS; NERVE DEGENERATION; NEUROPATHOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOPHYSIOLOGY; SENILE DEMENTIA; SENILE PLAQUE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; ANIMAL; DRUG EFFECTS; METABOLISM; THROMBOCYTE;

ALZHEIMER DISEASE; ANIMALS; BLOOD PLATELETS; DIABETES MELLITUS; HUMANS;

EID: 84911431191     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/156720501109141013115258     Document Type: Article

References (109)

1. Cummings JL. Alzheimer's disease. N Engl J Med 351: 56-67 (2004).
2. Helzner EP, Luchsinger JA, Scarmeas N, Cosentino S, Brickman AM, Glymour MM, et al. Contribution of vascular risk factors to the progression in Alzheimer disease. Arch Neurol 66: 343-348 (2009).
3. Chi NF, Chien LN, Ku HL, Hu CJ, Chiou HY. Alzheimer disease and risk of stroke: A population-based cohort study. Neurology 80: 705-711 (2013).
4. Tolppanen AM, Lavikainen P, Solomon A, Kivipelto M, Soininen H, Hartikainen S. Incidence of stroke in people with Alzheimer disease: a national register-based approach. Neurology 80: 353-358 (2013).
5. den Abeelen AS, Lagro J, van Beek AH, Claassen JA. Impaired cerebral autoregulation and vasomotor reactivity in sporadic Alzheimer's disease. Curr.Alzheimer Res 11: 11-17 (2014).
6. McEvoy M, Schofield P, Smith W, Agho K, Mangoni AA, Soiza RL, et al. Memory impairment is associated with serum methylarginines in older adults. Curr.Alzheimer Res 11: 97-106 (2014).
7. Deschaintre Y, Richard F, Leys D, Pasquier F. Treatment of vascular risk factors is associated with slower decline in Alzheimer disease. Neurology 2009 73: 674-680 (2009).
8. Forette F, Seux ML, Staessen JA, Thijs L, Babarskiene MR, Babeanu S, et al. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch Intern Med 162: 2046-2052 (2002).
9. Ahn HJ, Glickman JF, Poon KL, Zamolodchikov D, Jno-Charles OC, Norris EH, et al. A novel Abeta-fibrinogen interaction inhibitor rescues altered thrombosis and cognitive decline in Alzheimer's disease mice. J Exp Med 211: 1049-1062 (2014).
10. Jamieson GA, Urban CL, Barber AJ. Enzymatic basis for platelet: collagen adhesion as the primary step in haemostasis. Nat New Biol 234: 5-7 (1971).
11. Nachman RL, Rafii S. Platelets, petechiae, and preservation of the vascular wall. N Engl J Med 359: 1261-1270 (2008).
12. Sambrano GR, Weiss EJ, Zheng YW, Huang W, Coughlin SR. Role of thrombin signalling in platelets in haemostasis and thrombosis. Nature 413: 74-78 (2001).
13. Daub K, Seizer P, Stellos K, Kramer BF, Bigalke B, Schaller M, et al. Oxidized LDL-activated platelets induce vascular inflammation. Semin Thromb Hemost 36: 146-156 (2010).
14. Davi G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med 357: 2482-2494 (2007).
15. Gawaz M, Langer H, May AE. Platelets in inflammation and atherogenesis. J Clin Invest 115: 3378-3384 (2005).
16. Lindemann S, Kramer B, Daub K, Stellos K, Gawaz M. Molecular pathways used by platelets to initiate and accelerate atherogenesis. Curr Opin Lipidol 18: 566-573 (2007).
17. Stellos K, Bigalke B, Stakos D, Henkelmann N, Gawaz M. Platelet-bound P-selectin expression in patients with coronary artery disease: impact on clinical presentation and myocardial necrosis, and effect of diabetes mellitus and anti-platelet medication. J Thromb Haemost 8: 205-207 (2010).
18. von HP, Weber C. Platelets as immune cells: bridging inflammation and cardiovascular disease. Circ Res 100: 27-40 (2007).
19. Henn V, Slupsky JR, Grafe M, Anagnostopoulos I, Forster R, Muller-Berghaus G, et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 391: 591-594 (1998).
20. Stellos K, Langer H, Daub K, Schoenberger T, Gauss A, Geisler T, et al. Platelet-derived stromal cell-derived factor-1 regulates adhesion and promotes differentiation of human CD34+ cells to endothelial progenitor cells. Circulation 117: 206-215 (2008).
21. Stellos K, Bigalke B, Langer H, Geisler T, Schad A, Kogel A, et al. Expression of stromal-cell-derived factor-1 on circulating platelets is increased in patients with acute coronary syndrome and correlates with the number of CD34+ progenitor cells. Eur Heart J 30: 584-593 (2009).
22. von HP, Weber KS, Huo Y, Proudfoot AE, Nelson PJ, Ley K, Weber C. RANTES deposition by platelets triggers monocyte arrest on inflamed and atherosclerotic endothelium. Circulation 103: 1772-1777 (2001).
23. Borroni B, Colciaghi F, Caltagirone C, Rozzini L, Broglio L, Cattabeni F, Di LM, et al. Platelet amyloid precursor protein abnormalities in mild cognitive impairment predict conversion to dementia of Alzheimer type: a 2-year follow-up study. Arch Neurol 60: 1740-1744 (2003).
24. Davies TA, Long HJ, Tibbles HE, Sgro KR, Wells JM, Rathbun WH, et al. Moderate and advanced Alzheimer's patients exhibit platelet activation differences. Neurobiol.Aging 18: 155-162 (1997).
25. Johnston JA, Liu WW, Coulson DT, Todd S, Murphy S, Brennan S, et al. Platelet beta-secretase activity is increased in Alzheimer's disease. Neurobiol.Aging 29: 661-668 (2008).
26. Laske C, Leyhe T, Stransky E, Eschweiler GW, Bueltmann A, Langer H, et al. Association of platelet-derived soluble glycoprotein VI in plasma with Alzheimer's disease. J Psychiatr Res 42: 746-751 (2008).
27. Laske C, Sopova K, Stellos K. Platelet activation in Alzheimer's disease: from pathophysiology to clinical value. Curr Vasc Pharmacol 10: 626-630 (2012).
28. Li QX, Berndt MC, Bush AI, Rumble B, Mackenzie I, Friedhuber A, et al. Membrane-associated forms of the beta A4 amyloid protein precursor of Alzheimer's disease in human platelet and brain: surface expression on the activated human platelet. Blood 84: 133-142 (1994).
29. Prodan CI, Ross ED, Stoner JA, Cowan LD, Vincent AS, Dale GL. Coated-platelet levels and progression from mild cognitive impairment to Alzheimer disease. Neurology 76: 247-252 (2011).
30. Rosenberg RN, Baskin F, Fosmire JA, Risser R, Adams P, Svetlik D, et al. Altered amyloid protein processing in platelets of patients with Alzheimer disease. Arch Neurol 54: 139-144 (1997).
31. Sevush S, Jy W, Horstman LL, Mao WW, Kolodny L, and Ahn YS. Platelet activation in Alzheimer disease. ArchNeurol 55: 530-536 (1998).
32. Smith CC. Stimulated release of the beta-amyloid protein of Alzheimer's disease by normal human platelets. Neurosci Lett 235: 157-159 (1997).
33. Arvanitakis Z, Wilson RS, Bienias JL, Evans DA, Bennett DA. Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch Neurol 61: 661-666 (2004).
34. Cheng D, Noble J, Tang MX, Schupf N, Mayeux R, Luchsinger JA. Type 2 diabetes and late-onset Alzheimer's disease. Dement Geriatr Cogn Disord 31: 424-430 (2011).
35. Irie F, Fitzpatrick AL, Lopez OL, Kuller LH, Peila R, Newman AB, et al. Enhanced risk for Alzheimer disease in persons with type 2 diabetes and APOE epsilon4: the Cardiovascular Health Study Cognition Study. Arch Neurol 2008; 65: 89-93 (2008).
36. Luchsinger JA, Reitz C, Honig LS, Tang MX, Shea S, Mayeux R. Aggregation of vascular risk factors and risk of incident Alzheimer disease. Neurology 65: 545-551 (2005).
37. Xu W, Qiu C, Winblad B, Fratiglioni L. The effect of borderline diabetes on the risk of dementia and Alzheimer's disease. Diabetes 56: 211-216 (2007).
38. Xu WL, Qiu CX, Wahlin A, Winblad B, Fratiglioni L. Diabetes mellitus and risk of dementia in the Kungsholmen project: a 6-year follow-up study. Neurology 63: 1181-1186 (2004).
39. Janson J, Laedtke T, Parisi JE, O'Brien P, Petersen RC, Butler PC. Increased risk of type 2 diabetes in Alzheimer disease. Diabetes 53: 474-481 (2004).
40. Mehla J, Chauhan BC, Chauhan NB. Experimental induction of type 2 diabetes in aging-accelerated mice triggered Alzheimer-like pathology and memory deficits. J Alzheimers Dis 39: 145-162 (2014).
41. Hoppener JW, Ahren B, and Lips CJ. Islet amyloid and type 2 diabetes mellitus. N Engl J Med 343: 411-419 (2000).
42. Westermark P, Wernstedt C, Wilander E, Hayden DW, O'Brien TD, Johnson KH. Amyloid fibrils in human insulinoma and islets of Langerhans of the diabetic cat are derived from a neuropeptidelike protein also present in normal islet cells. Proc Natl Acad Sci USA 84: 3881-3885 (1987).
43. Moloney AM, Griffin RJ, Timmons S, O'Connor R, Ravid R, O'Neill C. Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling. Neurobiol Aging 31: 224-243 (2010).
44. Xie L, Helmerhorst E, Taddei K, Plewright B, Van BW, Martins R. Alzheimer's beta-amyloid peptides compete for insulin binding to the insulin receptor. J Neurosci 22: RC221, (2002).
45. Zhao WQ, Townsend M. Insulin resistance and amyloidogenesis as common molecular foundation for type 2 diabetes and Alzheimer's disease. Biochim Biophys Acta 1792: 482-496 (2009).
46. Biessels GJ, Kappelle LJ. Increased risk of Alzheimer's disease in Type II diabetes: insulin resistance of the brain or insulin-induced amyloid pathology? Biochem SocTrans 33: 1041-1044 (2005).
47. Zhang Y, Zhou B, Deng B, Zhang F, Wu J, Wang Y, Le Y, Zhai Q. Amyloid-beta induces hepatic insulin resistance in vivo via JAK2. Diabetes 62: 1159-1166 (2013).
48. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261: 921-923 (1993).
49. Zhao Q, Xiong Y, Ding D, Guo Q, Hong Z. Synergistic Effect between Apolipoprotein E epsilon4 and Diabetes Mellitus for Dementia: Result from a Population-Based Study in Urban China. J Alzheimers Dis 32: 1019-1027 (2012).
50. Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS). Lancet 357: 169-175 (2001).
51. Peila R, Rodriguez BL, a Launer LJ. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study. Diabetes 51: 1256-1262 (2002).
52. Petrovitch H, White LR, Ross GW, Steinhorn SC, Li CY, Masaki KH, Davis DG, et al. Accuracy of clinical criteria for AD in the Honolulu-Asia Aging Study, a population-based study. Neurology 57: 226-234 (2001).
53. Nelson PT, Smith CD, Abner EA, Schmitt FA, Scheff SW, Davis GJ, et al. Human cerebral neuropathology of Type 2 diabetes mellitus. Biochim Biophys Acta 1792: 454-469 (2009).
54. El HM and Rosado JA. Platelet signalling abnormalities in patients with type 2 diabetes mellitus: a review. Blood Cells Mol Dis 41: 119-123 (2008).
55. Geisler T, Anders N, Paterok M, Langer H, Stellos K, Lindemann S, et al. Platelet response to clopidogrel is attenuated in diabetic patients undergoing coronary stent implantation. Diabetes Care 30: 372-374 (2007).
56. Geisler T, Grass D, Bigalke B, Stellos K, Drosch T, Dietz K, et al. The Residual Platelet Aggregation after Deployment of Intracoronary Stent (PREDICT) score. J Thromb Haemost 6: 54-61 (2008).
57. Israels SJ, McNicol A, Dean HJ, Cognasse F, and Sellers EA. Markers of platelet activation are increased in adolescents with type 2 diabetes. Diabetes Care 37: 2400-2403 (2014).
58. Angiolillo DJ, Bernardo E, Sabate M, Jimenez-Quevedo P, Costa MA, Palazuelos J, et al. Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. J Am Coll Cardiol 50: 1541-1547 (2007).
59. Geisler T, Mueller K, Aichele S, Bigalke B, Stellos K, Htun P, Ninci E, Fateh-Moghadam S, May AE, and Gawaz M. Impact of inflammatory state and metabolic control on responsiveness to dual antiplatelet therapy in type 2 diabetics after PCI: prognostic relevance of residual platelet aggregability in diabetics undergoing coronary interventions. Clin Res Cardiol 99: 743-752 (2010).
60. Arthur JF, Shen Y, Chen Y, Qiao J, Ni R, Lu Y, et al. Exacerbation of glycoprotein VI-dependent platelet responses in a rhesus monkey model of Type 1 diabetes. J. Diabetes Res 2013: 370212, (2013).
61. Rosado JA, Saavedra FR, Redondo PC, Hernandez-Cruz JM, Salido GM, Pariente JA. Reduced plasma membrane Ca2+-ATPase function in platelets from patients with non-insulin-dependent diabetes mellitus. Haematologica 89: 1142-1144 (2004).
62. Randriamboavonjy V, Pistrosch F, Bolck B, Schwinger RH, Dixit M, Badenhoop K, et al. Platelet sarcoplasmic endoplasmic reticulum Ca2+-ATPase and mu-calpain activity are altered in type 2 diabetes mellitus and restored by rosiglitazone. Circulation 117: 52-60 (2008).
63. Kuchay SM, Chishti AH. Calpain-mediated regulation of platelet signaling pathways. Curr Opin Hematol 14: 249-254 (2007).
64. Randriamboavonjy V, Isaak J, Elgheznawy A, Pistrosch F, Fromel T, Yin X, et al. Calpain inhibition stabilizes the platelet proteome and reactivity in diabetes. Blood 120 (2): 415-23 (2012).
65. Koenen RR, von HP, Nesmelova IV, Zernecke A, Liehn EA, Sarabi A, et al. Disrupting functional interactions between platelet chemokines inhibits atherosclerosis in hyperlipidemic mice. Nat Med 15: 97-103 (2009).
66. Hunter RW, Hers I. Insulin/IGF-1 hybrid receptor expression on human platelets: consequences for the effect of insulin on platelet function. J Thromb Haemost 7: 2123-2130 (2009).
67. Stolla MC, Li D, Lu L, Woulfe DS. Enhanced platelet activity and thrombosis in a murine model of type I diabetes are partially insulin-like growth factor 1-dependent and phosphoinositide 3-kinase-dependent. J Thromb Haemost 11: 919-929 (2013).
68. Angiolillo DJ, Badimon JJ, Saucedo JF, Frelinger AL, Michelson AD, Jakubowski JA, et al. A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial. Eur Heart J 32: 838-846 (2011).
69. Evin G, Zhu A, Holsinger RM, Masters CL, Li QX. Proteolytic processing of the Alzheimer's disease amyloid precursor protein in brain and platelets. J Neurosci Res 74: 386-392 (2003).
70. Chen M, Inestrosa NC, Ross GS, Fernandez HL. Platelets are the primary source of amyloid beta-peptide in human blood. Biochem Biophys Res Commun 213: 96-103 (1995).
71. Piletz JE, Sarasua M, Whitehouse P, Chotani M. Intracellular membranes are more fluid in platelets of Alzheimer's disease patients. Neurobiol Aging 12: 401-406 (1991).
72. Mukaetova-Ladinska EB, Abdel-All Z, Andrade J, McNally RJ, James PW, Kalaria RN, et al. Increase in Platelet Immunoglobulin in Alzheimer's Disease is Normalised Following Cholinesterase Inhibitor Treatment: Preliminary Results. J Alzheimers Dis 32: 431-436 (2012).
73. Parker WD, Jr., Mahr NJ, Filley CM, Parks JK, Hughes D, Young DA, Cullum CM. Reduced platelet cytochrome c oxidase activity in Alzheimer's disease. Neurology 44: 1086-1090 (1994).
74. Colciaghi F, Marcello E, Borroni B, Zimmermann M, Caltagirone C, Cattabeni F, et al. Platelet APP, ADAM 10 and BACE alterations in the early stages of Alzheimer disease. Neurology 62: 498-501 (2004).
75. Dale GL. Coated-platelets: an emerging component of the procoagulant response. J Thromb Haemost 3: 2185-2192 (2005).
76. Prodan CI, Szasz R, Vincent AS, Ross ED, Dale GL. Coatedplatelets retain amyloid precursor protein on their surface. Platelets 17: 56-60 (2006).
77. Prodan CI, Ross ED, Vincent AS, Dale GL. Coated-platelets correlate with disease progression in Alzheimer disease. J Neurol 254: 548-549 (2007).
78. Prodan CI, Ross ED, Vincent AS, Dale GL. Rate of progression in Alzheimer's disease correlates with coated-platelet levels--a longitudinal study. Transl Res 152: 99-102 (2008).
79. Stellos K, Panagiota V, Kogel A, Leyhe T, Gawaz M, Laske C. Predictive value of platelet activation for the rate of cognitive decline in Alzheimer's disease patients. J Cereb Blood Flow Metab 30: 1817-1820 (2010).
80. Stellos K, Katsiki N, Tatsidou P, Bigalke B, Laske C. Association of Platelet Activation with Vascular Cognitive Impairment: Implications in Dementia Development? Curr Vasc Pharmacol 12 (1): 152-4 (2014).
81. Wang RT, Jin D, Li Y, Liang QC. Decreased mean platelet volume and platelet distribution width are associated with mild cognitive impairment and Alzheimer's disease. J Psychiatr Res 47: 644-649 (2013).
82. Matsushima H, Shimohama S, Fujimoto S, Takenawa T, Kimura J. Changes in platelet phospholipase C protein level and activity in Alzheimer's disease. Neurobiol Aging 16: 895-900 (1995).
83. Gattaz WF, Talib LL, Schaeffer EL, Diniz BS, Forlenza OV. Low platelet iPLA (2) activity predicts conversion from mild cognitive impairment to Alzheimer's disease: a 4-year follow-up study. J Neural Transm 121: 193-200 (2014).
84. Veeranna, Kaji T, Boland B, Odrljin T, Mohan P, Basavarajappa BS, et al. Calpain mediates calcium-induced activation of the erk1,2 MAPK pathway and cytoskeletal phosphorylation in neurons: relevance to Alzheimer's disease. Am J Pathol 165: 795-805 (2004).
85. Nixon RA, Saito KI, Grynspan F, Griffin WR, Katayama S, Honda T, et al. Calcium-activated neutral proteinase (calpain) system in aging and Alzheimer's disease. Ann NY Acad Sci 747: 77-91 (1994).
86. Saito K, Elce JS, Hamos JE, Nixon RA. Widespread activation of calcium-activated neutral proteinase (calpain) in the brain in Alzheimer disease: a potential molecular basis for neuronal degeneration. Proc Natl Acad Sci USA 90: 2628-2632 (1993).
87. Higuchi M, Iwata N, Matsuba Y, Takano J, Suemoto T, Maeda J, et al. Mechanistic involvement of the calpain-calpastatin system in Alzheimer neuropathology. FASEB J 26: 1204-1217 (2012).
88. Sinjoanu RC, Kleinschmidt S, Bitner RS, Brioni JD, Moeller A, Ferreira A. The novel calpain inhibitor A-705253 potently inhibits oligomeric beta-amyloid-induced dynamin 1 and tau cleavage in hippocampal neurons. Neurochem Int 53: 79-88 (2008).
89. Medeiros R, Kitazawa M, Chabrier MA, Cheng D, Baglietto-Vargas D, Kling A, et al. Calpain inhibitor A-705253 mitigates Alzheimer's disease-like pathology and cognitive decline in aged 3xTgAD mice. Am J Pathol 181: 616-625 (2012).
90. Park SY and Ferreira A. The generation of a 17 kDa neurotoxic fragment: an alternative mechanism by which tau mediates betaamyloid-induced neurodegeneration. J Neurosci 25: 5365-5375 (2005).
91. Watkins GR, Wang N, Mazalouskas MD, Gomez RJ, Guthrie CR, Kraemer BC, et al. Monoubiquitination promotes calpain cleavage of the protein phosphatase 2A (PP2A) regulatory subunit alpha4, altering PP2A stability and microtubule-associated protein phosphorylation. J Biol Chem 287: 24207-24215 (2012).
92. Qian W, Yin X, Hu W, Shi J, Gu J, Grundke-Iqbal I, et al. Activation of protein phosphatase 2B and hyperphosphorylation of Tau in Alzheimer's disease. J Alzheimers Dis 23: 617-627 (2011).
93. Raynaud F, Marcilhac A. Implication of calpain in neuronal apoptosis. A possible regulation of Alzheimer's disease. FEBS J 273: 3437-3443 (2006).
94. Gupta A, Bisht B, Dey CS. Peripheral insulin-sensitizer drug metformin ameliorates neuronal insulin resistance and Alzheimer'slike changes. Neuropharmacology 60: 910-920 (2011).
95. Li J, Deng J, Sheng W, Zuo Z. Metformin attenuates Alzheimer's disease-like neuropathology in obese, leptin-resistant mice. Pharmacol Biochem Behav 101: 564-574 (2012).
96. Chen Y, Zhou K, Wang R, Liu Y, Kwak YD, Ma T, et al. Antidiabetic drug metformin (GlucophageR) increases biogenesis of Alzheimer's amyloid peptides via up-regulating BACE1 transcription. Proc Natl Acad Sci USA 106: 3907-3912 (2009).
97. Moore EM, Mander AG, Ames D, Kotowicz MA, Carne RP, Brodaty H, et al. Increased risk of cognitive impairment in patients with diabetes is associated with metformin. Diabetes Care 36: 2981-2987 (2013).
98. Imfeld P, Bodmer M, Jick SS, Meier CR. Metformin, other antidiabetic drugs, and risk of Alzheimer's disease: a populationbased case-control study. J Am Geriatr Soc 60: 916-921 (2012).
99. Jahrling JB, Hernandez CM, Denner L, Dineley KT. PPARgamma recruitment to active ERK during memory consolidation is required for Alzheimer's disease-related cognitive enhancement. J Neurosci 34: 4054-4063 (2014).
100. Nenov MN, Laezza F, Haidacher SJ, Zhao Y, Sadygov RG, Starkey JM, et al. Cognitive enhancing treatment with a PPARgamma agonist normalizes dentate granule cell presynaptic function in Tg2576 APP mice. J Neurosci 34: 1028-1036 (2014).
101. Mandrekar-Colucci S, Karlo JC, Landreth GE. Mechanisms underlying the rapid peroxisome proliferator-activated receptorgamma-mediated amyloid clearance and reversal of cognitive deficits in a murine model of Alzheimer's disease. J Neurosci 32: 10117-10128 (2012).
102. Drucker DJ. Minireview: the glucagon-like peptides. Endocrinology 142: 521-527 (2001).
103. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 132: 2131-2157 (2007).
104. Hamilton A, Holscher C. Receptors for the incretin glucagon-like peptide-1 are expressed on neurons in the central nervous system. Neuroreport 20: 1161-1166 (2009).
105. Bak AM, Egefjord L, Gejl M, Steffensen C, Stecher CW, Smidt K, et al. Targeting amyloid-beta by glucagon-like peptide -1 (GLP-1) in Alzheimer's disease and diabetes. Expert Opin Ther Targets 15: 1153-1162 (2011).
106. Long-Smith CM, Manning S, McClean PL, Coakley MF, O'Halloran DJ, Holscher C, et al. The Diabetes Drug Liraglutide Ameliorates Aberrant Insulin Receptor Localisation and Signalling in Parallel with Decreasing Both Amyloid-beta Plaque and Glial Pathology in a Mouse Model of Alzheimer's Disease. Neuromolecular Med 15 (1): 102-14 (2013).
107. Yang Y, Zhang J, Ma D, Zhang M, Hu S, Shao S, Gong CX. Subcutaneous administration of liraglutide ameliorates Alzheimerassociated tau hyperphosphorylation in rats with type 2 diabetes. J Alzheimers Dis 37: 637-648 (2013).
108. Thoonsen H, Richard E, Bentham P, Gray R, van GN, De Haan RJ, et al. Aspirin in Alzheimer's disease: increased risk of intracerebral hemorrhage: cause for concern? Stroke 41: 2690-2692 (2010).
109. Sakurai H, Hanyu H, Sato T, Kume K, Hirao K, Kanetaka H, Iwamoto T. Effects of cilostazol on cognition and regional cerebral blood flow in patients with Alzheimer's disease and cerebrovascular disease: a pilot study. Geriatr Gerontol Int 13: 90-97 (2013).